No Data
No Data
Filament Health Reports Q2 Results
Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER
Jaguar Health Executes Out-License Deal With Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Press Release: FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
No Data
No Data